March 10, 2017

President Daniel S. Greenbaum
dgreenbaum@healtheffects.org
Principal Scientist Aaron J. Cohen, D.Sc.
acohen@healtheffects.org
Health Effects Institute
www.healtheffects.org

Dear President Greenbaum and Principal Scientist Cohen,

As a follow-up to our communications dating back to 2002, I am challenging the validity of a positive relationship between fine particulate matter (PM$_{2.5}$) and total mortality in the ACS CSP II cohort, as described in the 2000 HEI Reanalysis Report and the 2009 HEI Research Report 140. My challenge is based on the evidence in my forthcoming journal article “Fine Particulate Matter and Total Mortality in Cancer Prevention Study Cohort Reanalysis.”

In order to test the validity of my evidence, I request that you conduct a sensitivity analysis that produces tables similar to the California tables presented with your September 7, 2010 letter to CARB. Specifically, please produce tables which describe the PM$_{2.5}$ and mortality relationship in the CSP II cohort for the Ohio Valley states (Indiana, Kentucky, Ohio, Pennsylvania, and West Virginia) and for the remainder of the Continental United States. Also, please produce these same tables using the 1979-1983 EPA IPN PM2.5 data, which I used in my 2005 Inhalation Toxicology article, instead of the PM2.5 data used in the 2000 and 2009 HEI Reports.

Let me know if you need any clarification of this request.

I will be presenting my evidence on March 23, 2017 at the Heartland International Conference on Climate Change (ICCC) in Washington, DC. I will be updating my June 11, 2015 ICCC talk "EPA’s Clean Power Plan and PM2.5-related Co-benefits." I invite you to attend my talk and bring me the above requested tables. In addition, I will be discussing my PM$_{2.5}$ mortality evidence and the integrity of the 2000 and 2009 HEI Reports with officials from the House Science Committee, the House Energy Committee, the House Oversight Committee, the Senate Environment Committee, the US Environmental Protection Agency, the Alliance of Automobile Manufacturers, and the US Office of Research Integrity.

Thank you very much for your prompt attention to this important request.

Sincerely yours,

James E. Enstrom, Ph.D., M.P.H.
UCLA and Scientific Integrity Institute
jenstrom@ucla.edu

cc: HEI Vice President Robert O’Keefe <rokeefe@healtheffects.org>
HEI Director of Science Rashid Shaikh, Ph.D. <rshaikh@healtheffects.org>
HEI Board Member Linda Rosenstock, M.D. <lindarosenstock@ph.ucla.edu>